Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
作者： Niall Tebbutt , Dusan Kotasek , Howard A. Burris , Lee S. Schwartzberg , Herbert Hurwitz
DOI: 10.1007/S00280-015-2694-Y
关键词: Oncology 、 Medicine 、 Panitumumab 、 FOLFIRI 、 Internal medicine 、 Motesanib 、 Angiogenesis inhibitor 、 FOLFOX 、 Colorectal cancer 、 Clinical trial 、 Fluorouracil
摘要: Purpose This study assessed the safety, efficacy, and pharmacokinetics of motesanib, a multitargeted small molecule angiogenesis inhibitor, with without panitumumab, in combination FOLFIRI or FOLFOX patients metastatic colorectal cancer (mCRC).
springer.com
sci-hub.se 参考文章(41)
Jeffrey R. Infante, Tony R. Reid, Allen L. Cohn, William J. Edenfield, Terrence P. Cescon, John T. Hamm, Imtiaz A. Malik, Thomas A. Rado, Philip J. McGee, Donald A. Richards, Jamal Tarazi, Brad Rosbrook, Sinil Kim, Thomas H. Cartwright, Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study Cancer. ,vol. 119, pp. 2555- 2563 ,(2013) , 10.1002/CNCR.28112
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. ,vol. 136, ,(2015) , 10.1002/IJC.29210
George L. Jackson, Leah L. Zullig, S. Yousuf Zafar, Adam A. Powell, Diana L. Ordin, Ziad F. Gellad, David Abbott, James M. Schlosser, Janis Hersh, Dawn Provenzale, Using NCCN clinical practice guidelines in oncology to measure the quality of colorectal cancer care in the veterans health administration. Journal of The National Comprehensive Cancer Network. ,vol. 11, pp. 431- 441 ,(2013) , 10.6004/JNCCN.2013.0058
Timothy J Price, Eva Segelov, Matthew Burge, Daniel G Haller, Stephen P Ackland, Niall C Tebbutt, Christos S Karapetis, Nick Pavlakis, Alberto F Sobrero, David Cunningham, Jeremy D Shapiro, Current opinion on optimal treatment for colorectal cancer Expert Review of Anticancer Therapy. ,vol. 13, pp. 597- 611 ,(2013) , 10.1586/ERA.13.37
C.H. Köhne, R. Labianca, T. Price, W. Scheithauer, A. Sobrero, J. Tabernero, D. Aderka, S. Barroso, G. Bodoky, J.Y. Douillard, H. El Ghazaly, J. Gallardo, A. Garin, R. Glynne-Jones, K. Jordan, A. Meshcheryakov, D. Papamichail, P. Pfeiffer, I. Souglakos, S. Turhal, A. Cervantes, H.J. Schmoll, E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, B. Nordlinger, C.J. van de Velde, J. Balmana, J. Regula, I.D. Nagtegaal, R.G. Beets-Tan, D. Arnold, F. Ciardiello, P. Hoff, D. Kerr, ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Annals of Oncology. ,vol. 23, pp. 2479- 2516 ,(2012) , 10.1093/ANNONC/MDS236
Miguel Martin, Henri Roche, Tamas Pinter, John Crown, M John Kennedy, Louise Provencher, Frank Priou, Wolfgang Eiermann, Encarna Adrover, Istvan Lang, Manuel Ramos, Jean Latreille, Agnieszka Jagiełło-Gruszfeld, Tadeusz Pienkowski, Emilio Alba, Raymond Snyder, Sachin Almel, Janusz Rolski, Montserrat Munoz, Rebecca Moroose, Sara Hurvitz, Ana Baños, Henry Adewoye, Yong-Jiang Hei, Mary-Ann Lindsay, Matthieu Rupin, David Cabaribere, Yasmin Lemmerick, John R Mackey, Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncology. ,vol. 12, pp. 369- 376 ,(2011) , 10.1016/S1470-2045(11)70037-7
Robert J. Mayer, Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 25, pp. 4165- 4167 ,(2007) , 10.1200/JCO.2007.11.6582
J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, Rafael G. Amado, A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 672- 680 ,(2009) , 10.1200/JCO.2008.19.8135
H S Hochster, HORIZON I: Is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy? British Journal of Cancer. ,vol. 108, pp. 477- 478 ,(2013) , 10.1038/BJC.2013.20
Lee S Rosen, Lara Lipton, Timothy J Price, Neil D Belman, Ralph V Boccia, Herbert I Hurwitz, Joe J Stephenson Jr, Lori J Wirth, Sheryl McCoy, Yong-jiang Hei, Cheng-Pang Hsu, Niall C Tebbutt, The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer. ,vol. 13, pp. 242- 242 ,(2013) , 10.1186/1471-2407-13-242